|Day Low/High||240.02 / 246.84|
|52 Wk Low/High||177.05 / 264.97|
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
It becomes difficult for me to tell you where to run in these markets...
Straying from these names could land you in quicksand as the 4th quarter begins.
It is all about perception, and here are strong names to pick up on market weakness.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
Here are 3 ways to play these 3 stocks on earnings.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
Sooner or later, bargain hunters will say: 'Enough already. It can't be that bad.'
Forward looking valuations, except for Nvidia, are very low.
I think M&A activity will pick up markedly going forward across the industry.
Our 'bearish bets' show weak technical characteristics and have received recent quant downgrades.
TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Amgen and why Chaikin says to be careful of the stock.
The good news is that volatility is increasing. The bad news, for some, is that it moves in both directions.
This will be the ninth consecutive year when the big game tops that 100 million-viewers mark.
You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
Rent-A-Center, Foot Locker and AV Homes will get a nice holiday gift with the tax deal.
These favorite names in the volatile sector offer the potential for high rewards.
What to make of the divergent views of Amgen's shares.
* Thus far, my expectation of an "inside day" has been accurate. SPDR S&P 500 ETF has traded in a fifty cent range most of the day. * Bonds are at the day's highs. +$0.88. Yield on the 10-year U.S. note is down by 3.5 basis points to 2.32% (where y...
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: "The Good, the Bad and the Ugly" There was plenty of sector rotation today (but little overall movement), so let's move to the abbreviated Monarch Notes form of "Takeaw...